Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects

  title={Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects},
  author={Mar{\'i}a Alejandra Egui Rojo and Ignacio Moncada Iribarren and Joaqu{\'i}n Alberto Carballido Rodr{\'i}guez and Juan Ignacio Mart{\'i}nez-Salamanca},
  journal={Therapeutic Advances in Urology},
  pages={192 - 197}
Introduction: Peyronie’s disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex® for the… 

Tables from this paper

Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis
The current evidence suggests that CCH has a significant effect on treating PD, and could slow the disease progression in the acute phase or act as a substitute for patients unable or unwilling to undergo surgery.
Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease
Current evidence indicates that this is a minimally invasive, effective and generally well tolerated treatment option for patients with Peyronie’s disease.
Role of collagenase clostridium histolyticum in Peyronie’s disease
Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction.
Peyronie's disease: What's around the bend?
Further research is essential to develop novel, safe, and effective minimally invasive Peyronie's disease treatment options, with the promise of specific, targeted, and highly effective therapies on the horizon.
Collagenase Clostridium histolyticum in Peyronie’s disease: a guide to its use in the EU
In clinical trials, CCH significantly improved penile curvature deformity and reduced patient-reported bother associated with Peyronie’s disease, and is generally well tolerated.
Postmarketing Experience of Intralesional Collagenase Clostridium histolyticum (Xiaflex®) Injection in Men with Peyronie’s Disease
Corporal ruptures remain a concern as reported in the Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Study trials and close observation, rather than surgical intervention, may be an appropriate treatment option for selected patients.
Injection Therapy for Peyronie’s Disease
Penile traction therapy may prevent PD-related loss of penile length, if used diligently, and ILI of stem cells, while still in its infancy, offers hope for a more targeted treatment of the disease in the future.
Optimizing collagenase Clostridium histolyticum therapy for Peyronie’s disease using a novel approach with percutaneous needle tunnelling
To compare the efficacy and safety of a combined treatment of percutaneous needle tunnelling (PNT) and a modified collagenase Clostridium histolyticum (CCH) protocol (PNT/CCH) vs the modified
Clinical Value of Debriding Enzymes as an Adjunct to Standard Early Surgical Excision in Human Burns; A Systematic Review.
Surgical excision still remains the standard of care for burn wounds debridement, however, enzymatic debridgeement, especially Bromelain might help to reduce sessions for surgical debridements or area under graft as an adjunct treatment.


The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
  • G. Jordan
  • Medicine
    The journal of sexual medicine
  • 2008
The benefits of intralesional clostridial collagenase injections in this trial lend support to prior studies supporting its use in the management of Peyronie's disease.
The use of collagenase in the treatment of Peyronie's disease.
Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease.
There was a trend toward measured curvature improvement, and a significant gain in SPL in men using the combination therapy protocol, and length improvement is related to duration of use of the traction device.
Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture.
The natural history of Peyronie's disease.